Lambert-Eaton myasthenic syndrome against the background of thyroid cancer: a clinical case

Abstract

BACKGROUND: Lambert–Eaton myasthenic syndrome (G73.1 according to ICD-10) is a rare autoimmune disease associated with a presynaptic impairment of neuromuscular transmission due to the production of antibodies to voltage-gated calcium channels. The peculiarity of Lambert–Eaton myasthenic syndrome is manifested in a combination of increased muscle weakness and fatigue with the phenomenon of «working in» — an increase in the muscle strength against the background of muscle load after a short-term maximum contraction. Lambert-Eaton myasthenic syndrome is often associated with small cell lung cancer and very rarely develops with tumors of another localization.

CLINICAL CASE DESCRIPTION: We observed an 80-year-old patient with complaints of weakness and pain in the hips, shoulders, pelvic region, and half-ptosis of the eyelids. For half-ptosis of the eyelids, a differential diagnosis was conducted with myasthenia gravis. Stimulation electromyography revealed the M-response increment, i.e. the phenomenon of “working in”, which is typical for this syndrome. The examination revealed papillary thyroid cancer, which was later treated surgically.

CONCLUSION: This case illustrates Lambert–Eaton’s paraneoplastic myasthenic syndrome, a rare tumor form associated with thyroid cancer.

Keywords

Lambert–Eaton myasthenic syndrome / paraneoplastic syndrome / thyroid cancer / clinical case

References

[1] Eymard B, Stojkovic T, Sternberg D, et al. [Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy: The French National Congenital Myasthenic Syndrome Network experience. (In French)]. Rev Neurol (Paris). 2013;169(Suppl 1):S45–55. doi: 10.1016/S0035-3787(13)70060-2

[2] Davis J. Lambert-Eaton myasthenic syndrome. Springer Semin. Immunopathol. 1985;8(1-2):129–140. doi: 10.1007/BF00197251

[3] Davila HM. Molecular and functional diversity of voltage-gated calcium channels. Ann NY Acad Sci. 1999;(868):102–117. doi: 10.1111/j.1749-6632.1999.tb11281.x

[4] Wray D, Porter V. Calcium channel types at the neuromuscular junction. Ann NY Acad Sci. 1994;(681):356–367. doi: 10.1111/j.1749-6632.1993.tb22914.x

[5] Санадзе А.Г., Сиднев Д.В., Щербакова Н.И., Карганов М.Ю. Миастенический синдром Ламберта–Итона // Журнал неврологии и психиатрии им. С.С. Корсакова. 2008. Т. 108, № 3. С. 4–10. [Sanadze AG, Sidnev DV, Shcherbakova NI, Karganov MY. Lambert–Eaton Myasthenic syndrome. J Neurol Psychiatry named after S.S. Korsakov. 2008;108(3):4–10. (In Russ).]

[6] Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol. 1956;(187):612–616.

[7] Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888–1893. doi: 10.1212/wnl.42.10.1888

[8] Казачкина Е.О., Вознюк К.О., Хомятова М.Р. Миастенический синдром Ламберта–Итона: редкое аутоиммунное заболевание, ассоциируемое с раком // Теоретические и практические аспекты современной медицины: сборник статей по материалам I Международной научно-практической конференции. Новосибирск, 2017. С. 14–24. [Kazachkina EO, Voznyuk KO, Khommyatova MR. Lambert–Eaton myasthenic syndrome: A rare autoimmune disease associated with cancer. In: Theoretical and practical aspects of modern medicine: Collection of articles based on the materials of the I International Scientific and Practical Conference. Novosibirsk; 2017. Р. 14–24. (In Russ).]

[9] Санадзе А.Г., Сиднев Д.В., Карганов М.Ю. Антитела к потенциалзависимым кальциевым каналам и ацетилхолиновым рецепторам у больных с миастеническим синдромом Ламберта–Итона // Нейроиммунология. 2006. Т. 4, № 1-2. С. 40–43. [Sanadze AG, Sidnev DV, Karganov MY. Antibodies to potential-dependent calcium channels and to acetylcholine receptors in patients with Lambert–Eaton myasthenic syndrome. Neuroimmunology. 2006;4(1-2):40–43. (In Russ).]

[10] Щербакова Н.И., Пикин О.В., Рудниченко В.А., и др. Случай миастенического синдрома Ламберта–Итона на фоне бессимптомной мелкоклеточной карциномы лёгких // Неврологический журнал. 2014. Т. 19, № 2. С. 11–17. [Shcherbakova NI, Pikin OV, Rudnichenko VA, et al. A case of Lambert–Eaton myasthenic syndrome on the background of asymptomatic small cell lung carcinoma. Neurological J. 2014;19(2):11–17. (In Russ).] doi: 10.18821/1560-9545-2014-19-2-11-17

[11] Zivaljtvic M, Popovic S, Vujkov T. [Lambert–Eaton myasthenic syndrome: A rare manifestation of paraneoplastic syndrome in ovarian cancer: Case report. (In Serbian)]. Med Regled. 2008;58(9-10):495–497. doi: 10.2298/mpns0510495z

[12] Peris P, Del Olm J, Gratacos J, Munos J. The Lambert–Eaton myasthenic syndrome in association with rheumatoid arthritis. Dr J Rheunimatol. 1990;29(1):75–76. doi: 10.1093/rheumatology/29.1.75-a

[13] Lang B, Pinto A, Giovannini F, et al. Pathogenic autoantibodies in the Lambert–Eaton myasthenic syndrome. Ann NY Acad Sci. 2003;(998):187–195. doi: 10.1111/j.1749-6632.1998.tb10992.x

[14] Whitney K, McNamara J. Autoimmunity and neurological disease: Antibody modulation of synaptic transmission. Ann Rev Neurosci. 1999;(22):175–195. doi: 10.1146/annurev.neuro.22.1.175

[15] Deodhar A, Norden J, So Y, Bennet R. The association of systemic lupus erythematosus and Lambert–Eaton myasthenic syndrome. J Rheumatol. 1996;23(7):1292–1294.

RIGHTS & PERMISSIONS

Eco-Vector